GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.00+0.08 (+4.17%)
Close on Nov 17, 2026Market cap $90.49MP/E –Yield –
Genelux total assets
Total assets on the balance sheet at the end of each period.
Genelux's total assets was $26.21M at Jun 30, 2026. For fiscal 2025 it was $19.03M, down 45.2% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.03M | -45.2% |
| FY2024 | Dec 31, 2024 | $34.72M | +24.5% |
| FY2023 | Dec 31, 2023 | $27.89M | +404.3% |
| FY2022 | Dec 31, 2022 | $5.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.21M | -18.7% |
| Q1 FY2026 | Mar 31, 2026 | $32.37M | -17.0% |
| Q4 FY2025 | Dec 31, 2025 | $19.03M | -45.2% |
| Q3 FY2025 | Sep 30, 2025 | $24.99M | -38.0% |
| Q2 FY2025 | Jun 30, 2025 | $32.25M | -28.6% |
| Q1 FY2025 | Mar 31, 2025 | $38.99M | +58.0% |
| Q4 FY2024 | Dec 31, 2024 | $34.72M | +24.5% |
| Q3 FY2024 | Sep 30, 2024 | $40.27M | +18.2% |
| Q2 FY2024 | Jun 30, 2024 | $45.18M | +44.1% |
| Q1 FY2024 | Mar 31, 2024 | $24.68M | +68.8% |
| Q4 FY2023 | Dec 31, 2023 | $27.89M | +404.3% |
| Q3 FY2023 | Sep 30, 2023 | $34.07M | – |
| Q2 FY2023 | Jun 30, 2023 | $31.36M | – |
| Q1 FY2023 | Mar 31, 2023 | $14.62M | – |
| Q4 FY2022 | Dec 31, 2022 | $5.53M | – |
See a number that looks wrong?